{"id":"lacosamide-rapid-titration-1","safety":{"commonSideEffects":[{"rate":"13-53%","effect":"Dizziness"},{"rate":"7-13%","effect":"Headache"},{"rate":"7-17%","effect":"Nausea"},{"rate":"6-11%","effect":"Diplopia"},{"rate":"5-9%","effect":"Ataxia"},{"rate":"4-8%","effect":"Vomiting"},{"rate":"4-6%","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL58323","moleculeType":"Small molecule","molecularWeight":"250.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lacosamide is a functionalized amino acid that selectively enhances slow inactivation of voltage-gated sodium channels, which reduces repetitive neuronal firing and prevents seizure propagation. Unlike traditional sodium channel blockers, it does not significantly affect fast inactivation, resulting in a favorable safety profile. This mechanism makes it effective as an adjunctive antiepileptic agent.","oneSentence":"Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:24.287Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Primary generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT00350103","phase":"PHASE3","title":"A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06-30","conditions":"Painful Diabetic Neuropathy","enrollment":551},{"nctId":"NCT03607851","phase":"PHASE4","title":"Efficacy and Safety of Rapid Titration Protocols of Lacosamide","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-08-03","conditions":"Focal Epilepsy","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lacosamide - rapid titration 1","genericName":"Lacosamide - rapid titration 1","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity. Used for Partial-onset seizures (adjunctive therapy), Primary generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}